CO2022005904A2 - Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico - Google Patents

Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico

Info

Publication number
CO2022005904A2
CO2022005904A2 CONC2022/0005904A CO2022005904A CO2022005904A2 CO 2022005904 A2 CO2022005904 A2 CO 2022005904A2 CO 2022005904 A CO2022005904 A CO 2022005904A CO 2022005904 A2 CO2022005904 A2 CO 2022005904A2
Authority
CO
Colombia
Prior art keywords
hydroxybenzoyl
amino
caprylic acid
salt
pcsk9 inhibitor
Prior art date
Application number
CONC2022/0005904A
Other languages
English (en)
Inventor
Andreas Vegge
Simon Bjerregaard
Kaisa Naelapää
Ulrik Lytt Rahbek
Philip Jonas Sassene
Jorrit Jeroen Water
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CO2022005904A2 publication Critical patent/CO2022005904A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden un inhibidor de PCSK9, tal como un péptido de EGF(A), y una sal de ácido N-(8-(2- hidroxibenzoil)amino)caprílico. La invención se refiere además a procesos para la preparación de tales composiciones, y a su uso en medicina.
CONC2022/0005904A 2019-11-07 2022-05-05 Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico CO2022005904A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19207564 2019-11-07
PCT/EP2020/081244 WO2021089761A1 (en) 2019-11-07 2020-11-06 Solid compositions comprising a pcsk9 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
CO2022005904A2 true CO2022005904A2 (es) 2022-07-29

Family

ID=68502818

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0005904A CO2022005904A2 (es) 2019-11-07 2022-05-05 Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico

Country Status (13)

Country Link
US (1) US20230000949A1 (es)
EP (1) EP4054520A1 (es)
JP (1) JP2023500031A (es)
KR (1) KR20220112751A (es)
CN (1) CN114641275A (es)
AU (1) AU2020378624A1 (es)
BR (1) BR112022007718A2 (es)
CA (1) CA3154596A1 (es)
CO (1) CO2022005904A2 (es)
IL (1) IL291893A (es)
MX (1) MX2022004718A (es)
PE (1) PE20221458A1 (es)
WO (1) WO2021089761A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117580583A (zh) * 2021-06-25 2024-02-20 甘李药业股份有限公司 Pcsk9抑制剂和glp-1受体激动剂的药物组合
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023178324A1 (en) * 2022-03-17 2023-09-21 Bristol-Myers Squibb Company Pharmaceutical compositions comprising salts of salcaprozate and nicotinamide for improving oral bioavailability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
WO2001092206A1 (en) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Method of preparing salicylamides
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2498519T3 (es) 2006-09-07 2014-09-24 F. Hoffmann-La Roche Ag Un procedimiento para la fabricación de SNAC (SALCAPROZATO SÓDICO)
JP5902194B2 (ja) 2010-12-16 2016-04-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
RU2014101501A (ru) 2011-06-20 2015-07-27 Дженентек, Инк. Связывающие pcsk9 полипептиды и способы применения
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
RU2747877C2 (ru) 2016-01-13 2021-05-17 Ново Нордиск А/С Аналоги эфр(а) с заместителями - жирными кислотами

Also Published As

Publication number Publication date
MX2022004718A (es) 2022-06-08
AU2020378624A1 (en) 2022-04-21
EP4054520A1 (en) 2022-09-14
CN114641275A (zh) 2022-06-17
IL291893A (en) 2022-06-01
CA3154596A1 (en) 2021-05-14
PE20221458A1 (es) 2022-09-21
BR112022007718A2 (pt) 2022-07-12
KR20220112751A (ko) 2022-08-11
JP2023500031A (ja) 2023-01-04
WO2021089761A1 (en) 2021-05-14
US20230000949A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
CO2020009997A2 (es) Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
CO2022005904A2 (es) Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CL2020002797A1 (es) Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2022000578A2 (es) Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2022000575A2 (es) Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CL2018003697A1 (es) Interferón porcino pegilado y métodos de uso del mismo.
CL2019003324A1 (es) Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745)
MX353067B (es) Composiciones de peptidos de glp-1 y preparaciones de las mismas.
MX2013006171A (es) Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
CL2010000434A1 (es) Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica.
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
EA201390998A1 (ru) Препарат фторуглеродсвязанных пептидов
ECSP21067816A (es) Formulaciones farmacéuticas
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
CL2017003201A1 (es) Variantes de il-37
ES2517741B1 (es) Composición para reducir y/o prevenir la caída del cabello y/o estimular su crecimiento
CL2012002358A1 (es) Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12.
CL2019000099A1 (es) Factor vii de coagulación de larga duración y métodos para producir el mismo.
AR122297A1 (es) Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2024000463A2 (es) Forma polimórfica a de n-(8-(2- hidroxibenzoil)amino)caprilato de sodio
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas